Claims study finds tirzepatide beats semaglutide on adherence and targets

The wire

1. 01Retrospective claims and lab analysis of 10,702 naive and 5,577 non-naive matched pairs starting Mounjaro or Ozempic between May 2022 and May 2023 tracked 12-month outcomes.
2. 02Tirzepatide initiators showed higher adherence (60% vs 45% naive) and persistence, and lower diabetes pharmacy cost per responder at A1c under 5.7% ($45,300 vs $65,300).
3. 03Observational design and propensity matching cannot rule out residual confounding; the analysis was authored by Eli Lilly-affiliated researchers using Healthcare Integrated Research Database data.

From the source

Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes

Journal of managed care & specialty pharmacy · 2026 Oct · Hoog MM, Vallarino C, Maldonado JM et al.